retatrutide glp-1 gip glucagon triple agonist Synedica Targeting GLP-1, GIP & GCG
Description
How the dual GLP-1 and GIP mechanism works To understand why a dual agonist outperforms a single agonist, you need to understand what each receptor does independently and what happens when both are activated together

Together, these translate into real clinical benefit for patients

By indication type, the obesity/weight management segment is expected to show the highest growth at a notable CAGR during the predicted time

Dasoju S, Karim N, Amin J, Chaudary D
These combined effects powerfully reduce food intake and drive weight loss

Plans should also ensure Wegovy is added to a transition exclusion list to ensure only Part D eligible medically accepted indications are afforded a transition fill
